THE ROLE OF PATIENT-REPORTED OUTCOMES (PRO) AS PRIMARY ENDPOINTS IN THE EVALUATION OF MEDICINES APPROVED WITH PRO CLAIMS

被引：0
|
作者：
Caron, M. [1 ]
Emery, M. P. [1 ]
机构：
[1] MAPI Res Trust, Lyon, France
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72332-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A338 / A338
页数：1
相关论文
共 50 条
  • [41] PATIENT-REPORTED OUTCOMES (PRO'S) AND ECONOMICS IN PATIENTS WITH BACK PAIN IN GERMANY
    Breitscheidel, L.
    Kreyenberg, K.
    Stridde, E.
    Eichmann, F.
    VALUE IN HEALTH, 2008, 11 (06) : A649 - A649
  • [42] Exploration of Patient-Reported Outcomes (PRO) in metastatic breast cancer clinical studies
    Zhang, Lijun
    Zhou, Jiaxi
    QUALITY OF LIFE RESEARCH, 2017, 26 (01) : 119 - 119
  • [43] Assessing and demonstrating data saturation in qualitative patient-reported outcomes (PRO) research
    Kerr, Cicely
    Nixon, Annabel
    Wild, Diane
    QUALITY OF LIFE RESEARCH, 2010, 19 : 124 - 124
  • [44] Development of the Ulcerative Colitis Patient-Reported Outcomes (UC-PRO) Questionnaire
    Higgins, Peter D.
    Harding, Gale
    Patrick, Donald L.
    Revicki, Dennis A.
    Globe, Gary
    Viswanathan, Hema N.
    Trease, Sarah
    Fitzgerald, Kristina
    Borie, Dominique C.
    Leidy, Nancy K.
    GASTROENTEROLOGY, 2013, 144 (05) : S768 - S768
  • [45] DEVELOPMENT OF A CHECKLIST TO ASSESS THE QUALITY OF TRANSLATIONS OF PATIENT-REPORTED OUTCOMES (PRO) INSTRUMENTS
    Conway, K.
    Acquadro, C.
    VALUE IN HEALTH, 2009, 12 (03) : A31 - A31
  • [46] Impact of cancer screening results on patient-reported outcomes (PRO) and behavioral intentions
    Patrick, Donald
    Ross, Melissa
    Mulnick, Sarah
    Samuelson, Ashley
    Cong, Ze
    Chung, Karen
    Klein, Eric A.
    Reid, Robert Lawrence
    Lopatin, Margarita
    Fung, Eric T.
    Dilaveri, Christina A.
    Marinac, Catherine
    McDonnell, Charles H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] PATIENT-REPORTED OUTCOMES: ARE THEY WORTH IT? AN EXAMINATION IN PRO VALUE THROUGH CASE STUDIES
    DeMuro, C.
    Gnanasakthy, A.
    VALUE IN HEALTH, 2013, 16 (07) : A711 - A711
  • [48] IMPACT OF THE FDA DRAFT GUIDANCE ON PATIENT REPORTED OUTCOMES (PRO) LABEL CLAIMS FOR APPROVED DRUG PRODUCTS IN THE US: HAS IT MADE A DIFFERENCE?
    Mordin, M.
    Clark, M.
    Siersma, C.
    Copley-Merriman, K.
    Gnanasakthy, A.
    VALUE IN HEALTH, 2009, 12 (03) : A29 - A29
  • [49] A critical evaluation of regulatory guidance on patient reported outcomes (PROs) addressing the use of PRO measures and endpoints in clinical trials
    Claassens, L.
    Jones, D.
    Bottomley, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels
    Willke, RJ
    Burke, LB
    Erickson, P
    CONTROLLED CLINICAL TRIALS, 2004, 25 (06): : 535 - 552
12345